• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by CH. DISCOV. & NON-CLIN DEV OFF Myles David C.

    3/3/25 4:20:52 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OLMA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Myles David C.

    (Last) (First) (Middle)
    C/O OLEMA PHARMACEUTICALS, INC.
    780 BRANNAN ST

    (Street)
    SAN FRANCISCO CA 94103

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Olema Pharmaceuticals, Inc. [ OLMA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CH. DISCOV. & NON-CLIN DEV OFF
    3. Date of Earliest Transaction (Month/Day/Year)
    02/28/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $4.37 02/28/2025 A 205,000 (1) 02/27/2035 Common Stock 205,000 $0 205,000 D
    Explanation of Responses:
    1. 25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
    /s/ Shane Kovacs, Attorney-in-Fact 03/03/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OLMA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OLMA

    DatePrice TargetRatingAnalyst
    4/2/2024$24.00Buy
    Goldman
    1/30/2024$20.00Buy
    Citigroup
    7/21/2023$21.00Outperform
    Oppenheimer
    5/5/2023$16.00Overweight
    CapitalOne
    2/22/2023$12.00Outperform
    Credit Suisse
    7/6/2022$16.00Buy
    Canaccord Genuity
    6/9/2022$12.00Neutral → Buy
    H.C. Wainwright
    2/28/2022Neutral
    HC Wainwright & Co.
    More analyst ratings

    $OLMA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Olema Oncology to Participate in Upcoming Investor Conferences

      SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema", "Olema Oncology", NASDAQ:OLMA) a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: H.C. Wainwright 3rd Annual BioConnect Investor Conference Date: Tuesday, May 20, 2025 at 4:30 p.m. ETFormat: Fireside Chat Location: New York, NY T.D. Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO and EHADate: Tuesday, May 27, 2025 at 5 p.m. ETFormat: Fireside ChatLocation: Virtual Live webcasts and recor

      5/9/25 4:30:00 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN FRANCISCO, May 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 104,400 shares of the Company's common stock, effective as of May 1, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance wit

      5/2/25 4:30:00 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

      Activity in preclinical models of ovarian, prostate, and non-small cell lung cancer supports potential utility of OP-3136, a KAT6 inhibitor, in indications beyond breast cancerPatient recruitment ongoing in Phase 1 trial of OP-3136 as a monotherapy and in combination regimens in multiple solid tumor typesData to be presented at 2025 AACR Annual Meeting SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced preclinical data demonstrating the anti-tumor a

      4/25/25 1:00:00 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OLMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Bain Capital Life Sciences Investors, Llc bought $1,727,370 worth of shares (300,000 units at $5.76) and disposed of 3,500,000 shares (SEC Form 4)

      4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

      1/13/25 4:34:40 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Graham G. Walmsley sold $4,730,137 worth of shares (700,761 units at $6.75) and bought $4,730,137 worth of shares (700,761 units at $6.75) (SEC Form 4)

      4/A - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

      12/18/24 6:52:04 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Graham G. Walmsley sold $4,730,137 worth of shares (700,761 units at $6.75) (SEC Form 4)

      4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

      12/17/24 7:52:19 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OLMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CH. DISCOV. & NON-CLIN DEV OFF Myles David C.

      4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

      3/3/25 4:20:52 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF MEDICAL OFFICER Zojwalla Naseem

      4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

      3/3/25 4:19:32 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF LEGAL OFFICER Mitchell Shawnte

      4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)

      3/3/25 4:18:17 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OLMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Olema Pharmaceuticals with a new price target

      Goldman initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $24.00

      4/2/24 7:41:58 AM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Olema Pharmaceuticals with a new price target

      Citigroup initiated coverage of Olema Pharmaceuticals with a rating of Buy and set a new price target of $20.00

      1/30/24 7:36:41 AM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Olema Pharmaceuticals with a new price target

      Oppenheimer initiated coverage of Olema Pharmaceuticals with a rating of Outperform and set a new price target of $21.00

      7/21/23 7:55:18 AM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OLMA
    Leadership Updates

    Live Leadership Updates

    See more
    • Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 19,800 shares of the Company's common stock, effective as of March 3, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance w

      3/4/25 4:30:00 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary

      SAN FRANCISCO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Shawnte M. Mitchell, J.D., as Chief Legal Officer and Corporate Secretary. "We are pleased to welcome Shawnte to our executive team to lead our Legal function as we progress both our late-stage palazestrant programs and our OP-3136 KAT6 program through clinical development," said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. "Her extensive e

      2/18/25 7:00:00 AM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

      ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

      11/24/24 7:27:00 PM ET
      $LIAN
      $MGTX
      $OLMA
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $OLMA
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Olema Pharmaceuticals Inc.

      DEFA14A - Olema Pharmaceuticals, Inc. (0001750284) (Filer)

      4/28/25 4:35:04 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Olema Pharmaceuticals Inc.

      DEF 14A - Olema Pharmaceuticals, Inc. (0001750284) (Filer)

      4/28/25 4:30:15 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Olema Pharmaceuticals Inc.

      S-8 - Olema Pharmaceuticals, Inc. (0001750284) (Filer)

      3/18/25 4:26:46 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OLMA
    Financials

    Live finance-specific insights

    See more
    • Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

      Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients with ER+/HER2- advanced or metastatic breast cancer With a median follow-up of 12 months, median progression-free survival (PFS) has not been reached6-month PFS rate was 73% in all patients, 81% in patients with ESR1 mutations, 70% in ESR1 wild-type patients, and 68% in patients with prior CDK4/6 inhibitor treatment; data continue to mature Conference call today at 8:00 a.m. ET SAN FRANCISCO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA),

      12/10/24 7:00:00 AM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

      SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that it will present new data from the Phase 1b/2 clinical study of palazestrant (OP-1250) in combination with CDK4/6 inhibitor ribociclib at the San Antonio Breast Cancer Symposium (SABCS 2024) being held December 10-13, 2024, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Poster Details Title: A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib, in patien

      11/25/24 5:30:00 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

      Across 50 treated patients, palazestrant (OP-1250) in combination with ribociclib was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of either therapy85% clinical benefit rate (CBR) observed to date across all CBR-eligible patients supports promising preliminary efficacy profile of the palazestrant-ribociclib combination Olema will host an investor conference call today at 8:00 a.m. ET SAN FRANCISCO, May 15, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted the

      5/15/24 7:01:00 AM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OLMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Olema Pharmaceuticals Inc.

      SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

      12/11/24 4:30:15 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Olema Pharmaceuticals Inc.

      SC 13D/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

      12/4/24 7:49:50 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Olema Pharmaceuticals Inc.

      SC 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

      11/14/24 4:34:56 PM ET
      $OLMA
      Biotechnology: Pharmaceutical Preparations
      Health Care